Literature DB >> 19793499

When is evidence of lack of harm enough? Has the rosiglitazone controversy ended?

Anthony L McCall1.   

Abstract

Entities:  

Year:  2009        PMID： 19793499     DOI： 10.1007/s11892-009-0063-0

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   4.810


× No keyword cloud information.
  14 in total

Review 1.  Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association.

Authors:  Richard W Nesto; David Bell; Robert O Bonow; Vivian Fonseca; Scott M Grundy; Edward S Horton; Martin Le Winter; Daniel Porte; Clay F Semenkovich; Sidney Smith; Lawrence H Young; Richard Kahn
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

2.  Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death.

Authors:  George A Diamond; Leon Bax; Sanjay Kaul
Journal:  Ann Intern Med       Date:  2007-08-06       Impact factor: 25.391

3.  The rosiglitazone story--lessons from an FDA Advisory Committee meeting.

Authors:  Clifford J Rosen
Journal:  N Engl J Med       Date:  2007-08-08       Impact factor: 91.245

4.  Thiazolidinediones and clinical outcomes in type 2 diabetes.

Authors:  Ravi Retnakaran; Bernard Zinman
Journal:  Lancet       Date:  2009-06-06       Impact factor: 79.321

5.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

Authors:  Anushka Patel; Stephen MacMahon; John Chalmers; Bruce Neal; Laurent Billot; Mark Woodward; Michel Marre; Mark Cooper; Paul Glasziou; Diederick Grobbee; Pavel Hamet; Stephen Harrap; Simon Heller; Lisheng Liu; Giuseppe Mancia; Carl Erik Mogensen; Changyu Pan; Neil Poulter; Anthony Rodgers; Bryan Williams; Severine Bompoint; Bastiaan E de Galan; Rohina Joshi; Florence Travert
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

6.  Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.

Authors:  Sonal Singh; Yoon K Loke; Curt D Furberg
Journal:  JAMA       Date:  2007-09-12       Impact factor: 56.272

7.  Effect of various diuretic treatments on rosiglitazone-induced fluid retention.

Authors:  Janaka Karalliedde; Robin Buckingham; Margaret Starkie; Daniel Lorand; Murray Stewart; Giancarlo Viberti
Journal:  J Am Soc Nephrol       Date:  2006-11-08       Impact factor: 10.121

8.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

9.  A randomized trial of therapies for type 2 diabetes and coronary artery disease.

Authors:  Robert L Frye; Phyllis August; Maria Mori Brooks; Regina M Hardison; Sheryl F Kelsey; Joan M MacGregor; Trevor J Orchard; Bernard R Chaitman; Saul M Genuth; Suzanne H Goldberg; Mark A Hlatky; Teresa L Z Jones; Mark E Molitch; Richard W Nesto; Edward Y Sako; Burton E Sobel
Journal:  N Engl J Med       Date:  2009-06-07       Impact factor: 91.245

Review 10.  Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.

Authors:  Rodrigo M Lago; Premranjan P Singh; Richard W Nesto
Journal:  Lancet       Date:  2007-09-29       Impact factor: 79.321
View more
  1 in total

Review 1.  Update on the safety of thiazolidinediones.

Authors:  David C Lieb; Anthony L McCall
Journal:  Curr Diab Rep       Date:  2010-04       Impact factor: 4.810
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.